Live Breaking News & Updates on Clinical oncology annual meeting

Stay informed with the latest breaking news from Clinical oncology annual meeting on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical oncology annual meeting and stay connected to the pulse of your community

Ascentage Pharma Announces 2023 Annual Results


SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During the reporting period, Ascentage Pharma made further strides in revenue generation through its commercialized product, achieved...

China , Australia , Suzhou , Jiangsu , Canada , Philadelphia , Pennsylvania , United-states , Rockville , American , Ascentage-phara , Prnewswire-ascentage-pharma

Advancing Treatment Selection in CLL Management

Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.

United-states , United-kingdom , Chicago , Illinois , Milano , Lombardia , Italy , Italian , American , Eli-lilly , Zanubrutinib-brukinsa , Pirtobrutinib-jaypirca

AURKA Pathway Gains Ground as Targetable Option in Metastatic Breast Cancer

The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.

Mayo-clinic-in-rochester , Minnesota , United-states , American , Karthikv-giridhar , Tufiac-haddad , Antonio-dassoro , Houj-aurora , Digital-health , Mayo-clinic-comprehensive-cancer-center , Mayo-clinic-college-of-medicine , American-society-of-clinical-oncology-annual-meeting

Propulsion of Small Lymphocytic Lymphoma Clinical Trial

The global Small Lymphocytic Lymphoma Treatment market has significantly grown over the past few years and is expected to register rapid growth. Revenue...

Nanjing , Jiangsu , China , New-york , United-states , San-diego , California , Chongqing , American , Secura-bio , Telios-pharma , Cellectar-biosciences

Top 5 Most-Read Lung Cancer Articles of 2023

Our most-read content that featured lung cancer included articles on non–small cell lung cancer, how navigation programs can increase screening rates, and a potential link between antidepressants and lung cancer risk.

United-states , Rhode-island , American , National-comprehensive-cancer-network , American-society-of-clinical-oncology-annual-meeting , Study-finds-patient-navigation-program , Finds-patient-navigation-program-increases , Cancer-screening-rates , American-society , Clinical-oncology-annual-meeting , Meets-clinical-end-point

B7-H4 Offers Potential Treatment Target in a Variety of Solid Tumors

The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.

United-states , Illinois , Orlando , Florida , Japan , South-korea , Madrid , Spain , Australia , Chicago , American , Josephr-podojil

PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline Insights | 30+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |

PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline Insights | 30+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Eli-lilly , Ascentage-pharma , Linton-pharm , Novartis-pharmarmaceutical , Sandeep-joshi , Cellular-biomedicine-group-inc , Dizal-pharmaceuticals , Market-research , American-society-of-clinical-oncology-annual-meeting , Pfizer

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states , China , Shanghai , Hong-kong , American , Ben-atwell-alex-shaw , Zhou-yi , Nasdaq , Drug-administration , China-limited-nasdaq , Stock-exchange-of-hong-kong , Exchange-commission